BioLineRx Ltd. (BLRX) Institutional Ownership

Ownership Summary

According to SEC filings for the period ending September 2025, BioLineRx Ltd. (NASDAQ:BLRX) is held by 14 institutional firms.

• These investors collectively held 0.0% of the company's total shares outstanding in September 2025, down from 0.0% in June 2025.
• On a quarter-over-quarter basis, institutional holdings shifted by 25.25%, with a year-over-year a decrease of 56.25% in the count of filers.
• During the quarter, 6 institutions bought more BioLineRx shares, 2 sold shares, and 6 of the 14 total investors held their position steady.
• Collectively, institutional investors increased their stake in BioLineRx to 27.70K shares as of September 2025, a change that is up by 5.58K shares quarter on quarter and down 2.47Mn shares year over year.
• CITADEL ADVISORS LLC's holding of 10.02K shares as of September 30, 2025 makes it the primary institutional investor in BioLineRx, owning 0.00% of the stock.
• Among the most significant buyers of BioLineRx during September 2025 were CITADEL ADVISORS LLC (10.02K), UBS Group AG (6.32K), MORGAN STANLEY (4.41K), Tower Research Capital LLC (TRC) (39), Rockefeller Capital Management L.P. (12).
• Leading sellers of BioLineRx stock in September 2025 included SIMPLEX TRADING, LLC (14.01K), RHUMBLINE ADVISERS (1.21K).
• The top 10 institutional holders of BioLineRx for the quarter ending September 2025 included CITADEL ADVISORS LLC (10.02K), UBS Group AG (6.39K), MORGAN STANLEY (5.95K), RHUMBLINE ADVISERS (3.07K), WELLS FARGO & COMPANY/MN (1.75K), Nemes Rush Group LLC (250), NewEdge Advisors, LLC (107), SIMPLEX TRADING, LLC (105), Tower Research Capital LLC (TRC) (39), Rockefeller Capital Management L.P. (12).